Analysts Set Expectations for TARA Q1 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Equities research analysts at Lifesci Capital issued their Q1 2025 earnings per share estimates for Protara Therapeutics in a report released on Tuesday, March 11th. Lifesci Capital analyst C. Zhu anticipates that the company will post earnings per share of ($0.37) for the quarter. Lifesci Capital currently has a “Outperform” rating and a $22.00 price target on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. Lifesci Capital also issued estimates for Protara Therapeutics’ Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($1.93) EPS, Q1 2026 earnings at ($0.57) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.77) EPS and FY2026 earnings at ($2.67) EPS.

Several other equities analysts have also issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a research note on Thursday, March 6th. Guggenheim reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Protara Therapeutics in a research note on Friday, December 6th.

Protara Therapeutics Price Performance

Shares of TARA opened at $4.02 on Thursday. The firm has a 50 day simple moving average of $4.45 and a two-hundred day simple moving average of $3.46. Protara Therapeutics has a one year low of $1.60 and a one year high of $10.48. The company has a market cap of $82.93 million, a P/E ratio of -1.43 and a beta of 1.69.

Protara Therapeutics (NASDAQ:TARA) last issued its earnings results on Wednesday, March 12th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.09.

Institutional Trading of Protara Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of TARA. Janus Henderson Group PLC acquired a new stake in shares of Protara Therapeutics during the 4th quarter valued at $11,938,000. Adage Capital Partners GP L.L.C. bought a new stake in shares of Protara Therapeutics during the fourth quarter worth about $11,880,000. Toronto Dominion Bank acquired a new position in shares of Protara Therapeutics in the fourth quarter valued at approximately $11,030,000. Blackstone Inc. bought a new position in Protara Therapeutics in the 4th quarter valued at approximately $8,870,000. Finally, RA Capital Management L.P. raised its holdings in Protara Therapeutics by 78.9% in the 4th quarter. RA Capital Management L.P. now owns 3,400,000 shares of the company’s stock valued at $17,952,000 after buying an additional 1,500,000 shares during the last quarter. Institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.